{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":2,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":2,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"59afb3db9958","filters":{"venue":"PAGEPress (PAGEPress (Italy))"}},"results":[{"id":"W6981214836","doi":"","title":"DREAMM-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma, including subgroups with renal impairment and high-risk cytogenetics: Session: Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"PAGEPress (PAGEPress (Italy))","topic":"Radiation Effects in Electronics","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Discontinuation; Population; Multiple myeloma; Adverse effect; Renal function; Population study; Malignancy","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.008847762985695338,"gpt":0.1884282021824785,"spread":0.1795804391967832,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007776527,0.0002771473,0.0007845661,0.000139518,0.0001717454,0.0003485785,0.0002651582,0.0002760465,0.002976628],"category_scores_gemma":[0.0004864467,0.0001166907,0.0005761363,0.0001449717,0.0001108399,0.0003077187,0.000256054,0.000711876,0.0003782892],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006231421,"about_ca_system_score_gemma":0.0005347308,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004388047,"about_ca_topic_score_gemma":0.001948542,"domain_scores_codex":[0.9998237,0.00006408837,0.00001887902,0.00003593589,0.00003463565,0.00002272549],"domain_scores_gemma":[0.9997823,0.00004458843,0.00005624766,0.000009929307,0.00002114179,0.00008589833],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1770899,0.005517367,0.1231905,0.002587164,0.002323177,0.000419437,0.000388952,0.002972164,0.05353092,0.0004761705,0.04365792,0.5878464],"study_design_scores_gemma":[0.1554397,0.2196705,0.5180411,0.0006628192,0.003185537,0.004029578,0.0003025292,0.007586137,0.02000475,0.001098254,0.0698733,0.0001058685],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9805787,0.01052027,0.000690294,0.001855032,0.0001853758,0.0004136684,0.001506614,0.0001377672,0.004112326],"genre_scores_gemma":[0.9913644,0.002656664,0.001078453,0.0007106246,0.0001668175,0.0002358581,0.001857663,0.0000101,0.001919454],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002976628,"threshold_uncertainty_score":0.00995779,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W6981310148","doi":"","title":"DREAMM-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma: Session: Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"PAGEPress (PAGEPress (Italy))","topic":"Diverse Scientific and Economic Studies","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Pembrolizumab; Adverse effect; Multiple myeloma; Interim analysis; Safety profile; Clinical trial","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.04391471674687396,"gpt":0.2496703058719302,"spread":0.2057555891250563,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001705463,0.0008592412,0.001633884,0.0002721087,0.000319175,0.000623667,0.0007233126,0.0009498264,0.006862049],"category_scores_gemma":[0.0009500834,0.0003590165,0.001536001,0.0002094964,0.0002136226,0.0004478321,0.0004283099,0.001936449,0.001297304],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001139377,"about_ca_system_score_gemma":0.001323682,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001002532,"about_ca_topic_score_gemma":0.002460727,"domain_scores_codex":[0.9995111,0.0002307515,0.0000434416,0.00007486876,0.00007254993,0.00006725551],"domain_scores_gemma":[0.9992245,0.000132162,0.0001816954,0.00004101544,0.00007564599,0.0003449855],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5788638,0.038252,0.02733998,0.002123111,0.003850717,0.000278907,0.0002923717,0.00509049,0.07234762,0.0002452066,0.02446517,0.2468506],"study_design_scores_gemma":[0.2282118,0.6581166,0.08020385,0.0001714117,0.001889274,0.0005395862,0.00007305911,0.003267176,0.01341317,0.0002986242,0.01375008,0.00006540433],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9753738,0.007099416,0.001018053,0.001567336,0.0002683389,0.00338081,0.005279819,0.0003065676,0.005705762],"genre_scores_gemma":[0.9784856,0.002301787,0.003102699,0.001153896,0.0002803056,0.002886034,0.005082104,0.00004028446,0.006667255],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006862049,"threshold_uncertainty_score":0.02295583,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}